Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) Anadys' belief that ANA773 holds promise as a potential replacement for injectable interferon products in HCV therapy; (ii) Anadys' ability to seek and obtain partnership opportunities to further the development of ANA773; (iii) the ability to create well-tolerated, all oral combination regimens to treat hepatitis C; (iv) the potential to further improve response by combining ANA773 with other agents, including ribavirin; and (v) the potential for alternative dosing schedules to further improve pharmacological response to TLR7 activation. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA773 will not have unforeseen safety issues or will have favorable results in future clinical studies. Furthermore, Anadys cannot provide any assurances that it will be able to obtain a partnership around ANA773 or that the development of the program will be continued. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
(Date:10/22/2014)... 21, 2014 Influenza will affect as many as ... the United States as high as 49,000 ... spread is from person to person in respiratory droplets of ... way of death, but kills much fewer people each year ... by human fluids including sweat, saliva, blood and other bodily ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... Mich., June 17 GeneGo, Inc., a leading,provider ... announced,today that they were awarded a Phase I ... of a platform for functional data analysis in,cancer. ... Boston on the project. The system, MetaMiner (Oncology) ...
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
Cached Medicine Technology:GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer 2Pharmaxis Establishes Named Patient Program for Bronchitol 2
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... Sept. 12 Medina General Hospital and,University Hospitals ... of,Understanding in which Medina General has indicated its ... University Hospitals, network of,community- based hospitals. The agreement ... with final regulatory and governance approvals. "We,re ...
... METAIRIE, La., Sept. 12 OrthoSynetics(TM), the largest,provider ... has hired David Ward as Western Region Sales ... to serving our existing,doctors and practices, as well ... Roussos, president and CEO of OrthoSynetics(TM). "He,is yet ...
... Sept. 12 A Sept. 12 signing of ... NASA and the,National Institutes of Health in their ... entered into an agreement that helps,American scientists use ... health and diseases. The pact signals to researchers ...
... Reaches Out to Educate Chicagoans, CHICAGO, Sept. ... empower the people of Chicago, SAVE THE PATIENT, ... show on the Chicago Access Network (CAN-TV). "Community ... PM on CAN-TV, Channel 21., Monday,s program ...
... Youre whale watching in Alaska, longing for a margarita and ... did I get here" I hate the cold. Never finished ... from the Journal of Consumer Research finds that when we ... a wider array of options will sound appealing, potentially leading ...
... Former Food and Drug Administration,commissioners David Kessler and ... new legislation that strengthens prescription drug safety and,revamps ... panelists in a,conference hosted by American University and ... report from Pfizer at:, http://media.medialink.com/WebNR.aspx?story=33842 Registered ...
Cached Medicine News:Health News:Medina General Hospital and University Hospitals Agree to Pursue Affiliation 2Health News:David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager 2Health News:NASA and NIH Partner for Health Research in Space 2Health News:Health Knowledge Empowers the Public 2Health News:Wanting a bite of everything: Hungry people crave more variety 2
... Flexible excellence for patients and clinicians., ... Aestiva/5 anesthesia system, the Aestiva/5 MRI is ... systems with a fully functional, integrated ventilator. ... Gauss, 1.5 T active shielded magnet), the ...
... ventilator control panel is conveniently located on the ... angle whether standing or sitting. The ventilator control ... and numerics. The ventilator has CMV, PCV and ... available in two lengths facilitates both the placing ...
... The flexible, modular approach to meeting today's ... offers one of the best ergonomic solutions in ... to operate from any position. A revolving arm ... magazine and moveable patient cassette mean that there ...
... The Narkomed GS provides high quality ... interface. The proven technologies of the ... make the Narkomed GS user-friendly and ... high quality Narkomed GS is the ...
Medicine Products: